Natural Mucosal Barriers and COVID-19 in Children

Carl A. Pierce¹, Sharlene Sy², Benjamin Galen³, Doctor Y Goldstein⁴, Erika Orner⁴, Marla J. Keller³, Kevan C. Herold^{5*}# and Betsy C. Herold^{1,2*#}

¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; ²Department of Pediatrics, The Children's Hospital at Montefiore and Albert Einstein College of Medicine, Bronx, NY 10461; ³Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10461; ⁴Department of Pathology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10461; ⁵Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT 06520

#Contributed equally; *To whom correspondence should be addressed.

Abstract

COVID-19 is more benign in children compared to adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesized that a more robust early innate immune response to SARS-CoV-2 may protect against severe disease and compared clinical outcomes, viral copies and cellular gene and protein expression in nasopharyngeal swabs from 12 children and 27 adults upon presentation to the Emergency Department. SARS-CoV-2 copies were similar, but compared to adults, children displayed higher expression of genes associated with interferon signaling, NLRP3 inflammasome, and other innate pathways. Higher levels of IFN- α 2, IFN- γ , IP-10, IL-8, and IL-1 β protein were detected in nasal fluid in children versus adults. Anti-SARS-CoV-2 IgA and IgG were detected in nasal fluid from both groups and correlated negatively with mucosal IL-18. These findings suggest that a vigorous mucosal immune response in children compared to adults contributes to favorable clinical outcomes.

Introduction

Epidemiological studies have consistently shown that children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have a milder clinical course with significantly less morbidity and mortality than adults. The Centers for Disease Control (CDC) estimates that approximately 1.2-3.3% of total hospitalizations and less than 0.21% of deaths from coronavirus disease 2019 (COVID-19) are in children (1). This experience is in contrast to other respiratory viruses, such as influenza or respiratory syncytial virus, where disease manifestations in children are often more severe than adults (2). Several hypotheses have been proposed to explain why children are protected from more severe outcomes with COVID-19 including differences in expression of angiotensin-converting enzyme 2 (ACE2), the receptor for viral entry, resulting in lower viral loads, presence of antibodies to common cold coronaviruses that might provide partial protection, and a more robust innate response early in the course of infection that mitigates against a vigorous adaptive response (3, 4). However, recent studies have shown that ACE2 expression is not reduced in children and may actually be lower in adults (5). Surveys of children infected with COVID-19 have found that the amount of SARS-CoV-2 RNA detected in nasopharyngeal (NP) swabs is at least as high in children compared to adults (6). It is also unlikely that antibodies that are cross reactive to other viruses explain the clinical differences as we previously found that antibody levels to other common cold human coronaviruses (229E, NL63, HKU1) were similar in adults and children. In addition, although common cold coronavirus antibody levels may be boosted in response to SARS-CoV-2 infection, they do not provide protection (7, 8).

In a previous analysis of patients hospitalized with COVID-19, we found that serum levels of IL-17A and IFN γ collected early in the course of disease were higher in children versus adults and correlated significantly and inversely with age (7). The source of these cytokines did not appear to be peripheral blood mononuclear cells as adults had more robust T cell responses. These findings suggested that other cells, such as innate immune cells within the respiratory tract,

might be the source of the IL-17A and IFN- γ and that a more vigorous mucosal innate response could account for the milder clinical course in children. To test the hypothesis that age-related outcomes reflect differences in host responses at the site of viral exposure, we collected nasopharyngeal (NP) swabs from pediatric and adult patients who presented to the Emergency Department at Montefiore Medical Center in The Bronx, NY, analyzed the harvested cells for gene expression, and measured the levels of cytokines and antibodies in the mucosa.

Results and Discussion

The demographics and clinical characteristics of the study population are described in Table S1. There were no significant differences in number of days of symptoms prior to presentation or the levels of SARS-CoV-2 viral RNA (quantified by cycle threshold [Ct] values) in NP swabs comparing the pediatric (n=12) and adult (n=27) patients (Fig. 1A). However, the outcomes differed. Adults were more likely to be admitted to the hospital (81% vs 42%, $p=0.02$), had higher C-reactive protein (10.48 ± 7.19 vs 6.03 ± 10.48 mg/dl, $p<0.0001$) and D-dimer (2.38 ± 3.42 vs 0.81 ± 0.59 μ g/ml, $p<0.0001$) at admission, and if hospitalized, had a longer length of stay (10.36 ± 10.85 vs 3.0 ± 1.73 days, $p<0.0001$) (Table S1). None of the pediatric patients required oxygen whereas 7 adults did and 4 required mechanical ventilation ($p=0.03$). Four adults but none of the pediatric patients died.

To evaluate whether the age-related differences in outcomes reflect differences in host responses at the site of viral exposure, the nasal mucosa, we performed RNA-Seq on cells isolated from NP swabs obtained at the time of presentation to the Emergency Department (n=6 pediatric and 15 adult patients). We identified 538 differentially expressed genes ($p<0.05$ after FDR correction) including 267 that were upregulated and 271 that were downregulated comparing pediatric and adult patients (Fig. 1B). Notably, expression of ACE2 trended towards being higher in the pediatric samples ($p=0.053$, Fig 1A).

Principal component analysis (PCA) of the RNAseq dataset separated pediatric and adult patients into non-overlapping clusters with the first dimension capturing 18.4% of the overall variance, the second dimension capturing 12.9% and the third 7.9% (Fig. 1C). To understand the gene expression patterns contributing to the segregation of the samples, we interrogated the 50 genes contributing most strongly to the principal components (Table S2). This gene set was enriched for interferon-stimulated and other innate immune response genes such as IL-1 β , CCL3, CXCL10, and NLRP3 (Fig. 1D). After dichotomization of adults by clinical outcome, PCA analysis showed that adults who never required supplemental oxygen were intermediate between adults who required respiratory support and children (Figure S1).

Given the strong contribution of innate immune gene expression in our PCA, we performed Gene Set Enrichment Analysis to evaluate the immune landscape. This showed enrichment of genes in the IFN- γ response (hallmark:M5913, Normalized Enrichment Score (NES)=3.66, $p=0.006$), IFN- α response (hallmark:M5911, NES=3.52, $p=0.006$), IL-1 response (GO:0070555, NES=2.70, $p=0.03$), NLRP3 inflammasome (GO:0072559, NES=1.88, $p=0.03$), and IL-17 production (GO:0032620, NES=2.30, $p=0.03$) in pediatric relative to adult patients (Fig. 2A). Conversely, fatty acid metabolism (hallmark:M5935, NES=-1.86, $p=0.006$) was enriched in adults compared to pediatric patients (Fig. 2B). Oxidative phosphorylation and glycolysis pathways were also increased in adults versus children, but these were not statistically different after FDR correction (NES=-1.18, $p=0.14$; NES=-1.09, $p=0.3$, respectively). These findings further support an enhanced innate response to SARS-CoV-2 infection in children but enhanced metabolic pathways among cells from adults.

We then performed RT-qPCR using RNA isolated from NP swabs from an additional 4 pediatric and 5 adult patients who were not included in the RNA-Seq analysis to confirm these findings. IL-17A gene expression was significantly increased in children (Fig. 2C) and there were similar trends for higher levels of IFN response genes (Figure S2). We also measured cytokine

levels in NP fluid and found significantly higher levels of IFN- γ , IFN- α 2, and IL-1 β , IL-8 and IP10 in pediatric patients (Fig. 2D-H), consistent with the RNAseq data.

SARS-CoV-2-specific IgA in nasal mucosal secretions may contribute to protection (9) and our RNA-Seq data revealed a cluster of B cell-associated genes in the PCA gene set (Dim 2; *IGHA1*, *IGKC*, *IGHM*, *IGHG1*, *FAM30A* and *PAX5*) with higher expression in a subset of both adult and pediatric samples (Fig 1D). Therefore, we measured total IgA and IgG by ELISA and SARS-CoV-2 specific IgA and IgG targeting S1, S2, and the receptor binding domain (RBD) of the spike and nucleocapsid (NC) protein by multiplex assay in the NP fluid. We did not identify differences in total IgG or IgA comparing pediatric and adult patients (Fig. 3A, C). While COVID-19 patients had elevated levels of SARS-CoV-2-specific immunoglobulins compared to healthy controls (n=7 adults), there were no significant differences between age groups (Fig. 3B, D). Agglomerative hierarchical clustering using only the B cell-associated genes dichotomized the cohort into a “low” or a “high” expression group (Fig. 3E). All of the adult patients with more severe clinical disease who required supplemental oxygen (SO) were in the low transcript group (Fig. 3E).

Correlation matrices were generated to explore possible associations between NP antibody levels, cytokines, and SARS-CoV-2 Ct values (Fig. 4A). In general, antibodies and cytokines did not strongly correlate with one another. However, we observed a significant and inverse relationship between SARS-CoV-2-specific antibodies (IgG and IgA) and IL-18 (Fig. 4C, D). There were no differences in IL-18 levels comparing children and adults, but there was a trend towards lower IL-18 in adults who required supplemental oxygen (Fig. 4B, p=0.12).

Our studies identify age-related differences in primary immune responses to SARS-CoV-2 at the nasal mucosa, the presumptive site of first viral encounter, which may contribute to the clinical outcomes. Most studies focus on systemic immune responses and have measured cytokines and antibodies in the blood, but our prior and other studies led us to speculate that the innate immune response was more vigorous in children (7). Our new findings using NP swabs

obtained at the earliest time point of presentation establish this and suggest that a more robust mucosal innate response in children overcomes viral evasion strategies and generates an immediate barrier to viral infection. This may dampen the subsequent adaptive immune response as evidenced by our prior findings of lower neutralizing antibodies, decreased antibody-dependent cell mediated phagocytic activity (ADCP), and less robust T cell responses in children versus adults (7). A reduced adaptive response in children compared to adults has been confirmed by others who documented decreased neutralizing antibody titers (10) and less robust T cell responses (11).

In contrast, a reduced or delayed mucosal response in adults, evidenced by the decreased expression of transcripts associated with innate pathways in their NP swabs may lead to an inability to escape viral immune evasion and a more vigorous adaptive response (12, 13). The latter contributes to high systemic levels of other inflammatory cytokines (e. g. IL-6 and TNF) and an increased risk of acute respiratory distress syndrome, which has also been observed with SARS-CoV-1 (14-17). Other studies have found an impaired innate response to SARS-CoV-2 in adults compared to other respiratory viral infections (18).

Children have more frequent respiratory infections than adults. This, as well as recent childhood immunizations, could contribute to a higher basal level of activation of innate responses as suggested by studies of rhinovirus in which an early interferon response was associated with rapid viral clearance (19). Notably, a recent study found that infection of organoid cultures with rhinovirus protected against subsequent SARS-CoV-2 challenge (20). The prior respiratory infections in children may prime innate immune cells that can rapidly respond to virus. The higher gene expression of metabolic flux pathways in adults may reflect the metabolic demands needed to activate innate pathways (21) and may account for a delayed response to COVID-19 (22).

We detected similar levels of SARS-CoV-2 specific IgA and IgG in NP samples obtained from adults and children at this early time point before a fully mature antibody response would be expected. Notably these early antibody responses correlated inversely with mucosal IL-18 levels.

IL-18, an IL-1 superfamily cytokine predominantly produced by macrophages, is cleaved to its active form by the NLRP3 inflammasome and ultimately promotes the production of IFN- γ . We speculate that the early release of this cytokine may temper the adaptive response which is consistent with the more severe outcomes with lower levels of IL-18. The kinetics of its secretion may be important since at later time points, elevated serum IL-18 levels are associated with increased inflammasome activation and disease severity (23).

In summary, we show, for the first time, direct evidence for a more vigorous early innate immune response in the nasopharynx of children compared to adults at clinical presentation with COVID-19. Innate immune responses to other pathogens have also been shown to decrease with age (24, 25). The cellular source of these protective cytokines is not clear but could include mucosal and airway epithelial or invariant natural killer T cells (26, 27). Nonetheless, our findings suggest that airway resident cells establish the response to virus that ultimately determines the clinical outcomes. The reasons for the differences in the early innate responses with age are not clear, but therapies that enhance these pathways may be an effective form of treatment and protect from further damage from viral invasion as suggested by ongoing trials of inhaled interferon beta-1 for early treatment of COVID-19 (28).

Methods

Study design

NP swabs were obtained from the Montefiore Clinical Laboratory from patients with confirmed SARS-CoV-2 infection by PCR assay who presented to the Emergency Department at Montefiore Medical Center between November 2020 and January 2021. Patients were excluded if they had pre-existing medical conditions that might impact immune responses including cancer and HIV, pregnancy, or were receiving chronic immunosuppressive therapy. Demographics, length of stay, peak respiratory support required (1=room air, 2=nasal cannula; 3=CPAP or high flow nasal oxygen, and 4=mechanical ventilation), outcome and the results of clinical laboratory

studies including SARS-CoV-2 PCR (Ct values), complete blood counts, D-dimer, and C-reactive protein were obtained by chart review.

The NP swabs were collected in viral transport medium. A portion was removed for measurement of SARS-CoV-2 RNA by PCR in the Clinical Microbiology Lab and the remainder of the sample was transported. NP swabs were also obtained from 7 healthy controls. The swab was transferred to a tube containing media supplemented with 13 μ M dithiotrietol to inactivate virus and then incubated in a thermomixer for 10 minutes at 37°C and 500 RPM. The cells were washed and frozen in 500 μ l 90% FBS/10% DMSO. The original transport medium (nasal fluid) was aliquoted and stored at -80°C for measurement of cytokines and antibodies.

RNA sequencing

RNA was isolated from cryopreserved cells using the miRNEasy Micro kit (Qiagen 217084). Samples with sufficient RNA quantity and quality were used for analysis. The methods for library preparation, sequencing, and analysis are discussed in Supplementary Methods. For quantitative RT-PCR, RNA was isolated as for RNAseq and cDNA synthesis was performed with methods described in Supplementary Methods.

Cytokine and Antibody Measurements

Media from NP swabs was thawed and treated with UV light to inactivate virus prior to use. SARS-CoV-2-specific IgG and IgA were measured using MILLIPLEX SARS-CoV-2 Antigen Panel 1 IgG and IgA kits (Millipore HC19SERG1-85K and HC19SERA1-85K, respectively). Cytokines were measured using the MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A kit (Millipore, HCYTA-60K).

Statistical Analyses

Because of sample volume limitations not all assays could be performed with all samples. Missing data was at random and the number of samples used are indicated. Statistical analyses were performed in GraphPad Prism (v9.0.1, GraphPad Software, Inc). Cytokine and antibody data were

log transformed prior to analysis. Normality was tested and a parametric or non-parametric test was used for comparison of groups as indicated.

Study Approval: This study was approved by the Institutional Review Board of the Albert Einstein College of Medicine (IRB# 2020-11278). Written informed consent was obtained for samples from healthy controls.

Author Contributions

Study design: CAP, KCH, BCH; Performance of experiments: CAP; Data acquisition and analysis: BG, SS, DYG, EO, MJK; Writing and editing: CAP, MJK, BCH, KCH.

Acknowledgments:

Supported by NIH grants R01 AI134367 (BCH and KCH), UL1 TR002556, P30 AI124414, an Einstein College of Medicine Dean's COVID-19 Pilot Research Award (BH). CAP is supported by T32 AI007501, NIGMS MSTP training grant T32GM007288 and The Eric J. Heyer, MD, PhD Translational Research Pilot Project Award.

References

1. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(15):458-64.
2. Doyle JD, and Campbell AP. Pediatric influenza and illness severity: what is known and what questions remain? *Curr Opin Pediatr.* 2019;31(1):119-26.
3. Weatherhead JE, Clark E, Vogel TP, Atmar RL, and Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. *J Clin Invest.* 2020;130(12):6194-7.
4. Bunyavanich S, Do, A. & Vicencio, A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA.* 2020;323:242702429.
5. Zhang Z, Guo L, Huang L, Zhang C, Luo R, Zeng L, et al. Distinct disease severity between children and older adults with COVID-19: Impacts of ACE2 expression, distribution, and lung progenitor cells. *Clin Infect Dis.* 2021.
6. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, and Kociolek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). *JAMA Pediatr.* 2020.
7. Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Sci Transl Med.* 2020;12(564).
8. Anderson EM, Goodwin, E.C, Verma, A , Arevalo, C. P., Bolton, M.J....Hensely, S.E. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell.* 2021;<https://doi.org/10.1016/j.cell.2021.02.010>.

9. Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med*. 2021;13(577).
10. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat Immunol*. 2021;22(1):25-31.
11. Moratto D, Giacomelli M, Chiarini M, Savare L, Saccani B, Motta M, et al. Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults. *Eur J Immunol*. 2020;50(9):1412-4.
12. Chen DY, Khan N, Close BJ, Goel RK, Blum B, Tavares AH, et al. SARS-CoV-2 desensitizes host cells to interferon through inhibition of the JAK-STAT pathway. *bioRxiv*. 2020.
13. Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. *Nat Commun*. 2020;11(1):3810.
14. Quartuccio L, Fabris M, Sonaglia A, Peghin M, Domenis R, Cifu A, et al. Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. *Cytokine*. 2021;140:155438.
15. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*. 2020;8(4):420-2.
16. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. *Clinical Infectious Diseases*. 2020.

17. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI Insight*. 2019;4(4).
18. Mick E, Kamm J, Pisco AO, Ratnasiri K, Babik JM, Castaneda G, et al. Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses. *Nat Commun*. 2020;11(1):5854.
19. Ravi A, Chang M, van de Pol M, Yang S, Aliprantis A, Thornton B, et al. Rhinovirus-16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms. *Clin Exp Allergy*. 2019;49(12):1587-97.
20. Nagarjuna R. Cheemarla TAW, Valia T. Mihaylova, Bao Wang, Dejian Zhao, Guilin Wang, Marie L. Landry, Ellen F. Foxman. Magnitude and timing of the antiviral response determine SARS-CoV-2 replication early in infection. *medRxiv*. 2021.
21. Ganeshan K, and Chawla A. Metabolic regulation of immune responses. *Annu Rev Immunol*. 2014;32:609-34.
22. Park A, and Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe*. 2020;27(6):870-8.
23. Rodrigues TS, de Sa KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp Med*. 2021;218(3).
24. Molony RD, Nguyen JT, Kong Y, Montgomery RR, Shaw AC, and Iwasaki A. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. *Sci Signal*. 2017;10(509).
25. Liang S, Domon H, Hosur KB, Wang M, and Hajishengallis G. Age-related alterations in innate immune receptor expression and ability of macrophages to respond to pathogen challenge in vitro. *Mech Ageing Dev*. 2009;130(8):538-46.

26. Farin HF, Karthaus WR, Kujala P, Rakhshandehroo M, Schwank G, Vries RG, et al. Paneth cell extrusion and release of antimicrobial products is directly controlled by immune cell-derived IFN-gamma. *J Exp Med*. 2014;211(7):1393-405.
27. Sharma M, Sharma S, Roy S, Varma S, and Bose M. Pulmonary epithelial cells are a source of interferon-gamma in response to Mycobacterium tuberculosis infection. *Immunol Cell Biol*. 2007;85(3):229-37.
28. Monk PD, Richard JMarsden, Victoria J Tear, Jody Brookes, Toby N Batten, Marcin Mankowski, Felicity J Gabbay, Donna E Davies, Stephen T Holgate, Ling-Pe Ho, Tristan Clark, Ratko Djukanovic, Tom M A Wilkinson, , and Group IIBC-S. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respiratory Medicine*. 2021;9(2):196-206.
29. Patro R, Duggal G, Love MI, Irizarry RA, and Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods*. 2017;14(4):417-9.
30. Love MI, Huber W, and Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.

Figure 1: Transcriptional profiles in pediatric and adult nasopharyngeal samples. (A) Cycle threshold (Ct) values and days of symptoms prior to presentation in 27 adult and 11 pediatric patients, and ACE2 read counts in cells isolated from NP swabs obtained at presentation in 15 adult and 6 pediatric samples. Bars show mean ± 95% CI. (B) Volcano plot of genes expressed more strongly in pediatric (right) and adult (left) patients. (C) Principal component plot of RNAseq data; n = 15 adult and 6 pediatric samples. Ovals are 95% confidence ellipses. (D) Heatmap showing expression of the top fifty contributing genes in principal components one, two, and three.

Figure 2: Innate responses in pediatric and adult nasopharynx. (A) Gene set enrichment plots for the indicated pathways: IFN- γ response (Normalized Enrichment Score (NES)=3.66, p =0.006), IFN- α response (NES=3.52, p =0.006), IL-1 response (NES=2.70, p =0.03), NLRP3 inflammasome (NES=1.88, p =0.03), and IL-17 production (NES=2.30, p =0.03). (B) Fatty acid metabolism (NES=-1.86, p =0.006). All plots show enrichment in RNAseq data from pediatric patients relative to adult patients. (C) Relative IL-17A gene expression measured by RT-qPCR in 5 adult and 4 pediatric samples not used for RNAseq. Fold change was calculated by the $2^{CT(ref)-CT}$ method using the mean adult value as the reference. (D-H) Levels of the indicated cytokines in NP transport media from 25 adult and 9 pediatric patients measured by multiplex Luminex assay. p -values are listed above comparison bars. Unpaired t-test (G, H) or Mann Whitney test (C-F). Ped = pediatric. Bars show mean $\pm$ 95% CI.

Figure 3: Early mucosal antibody responses in pediatric and adult COVID-19 patients. (A) Total and (B) SARS-CoV-2 specific IgA and (C) total and (D) SARS-CoV-2 specific IgG levels at time of presentation were measured in 10 pediatric and 25 adult patients and 7 healthy controls (HC). (E) Heatmap showing expression of B cell-related genes contributing to PC1-3. Annotations show age group and peak respiratory score (1 = Room Air, 2-4 = Supplemental Oxygen). Total antibody levels (A, C) measured by ELISA; SARS-CoV-2 antibody levels (B, D) measured by multiplexed Luminex assay. Where significant, p-values are listed above comparison bars; Kruskal-Wallis (B, D). Ped. = pediatric. Bars show mean ± 95% CI.

Figure 4: Nasopharyngeal IL-18 levels negatively correlate with SARS-CoV-2-specific mucosal antibody. (A) Spearman correlation matrix of Ct values, antibody, and cytokine data. **(B)** IL-18 levels in pediatric patients and adults who did not (RA) or did (SO) require supplemental oxygen. **(C)** Correlations between IL-18 and SARS-CoV-2-specific IgG. **(D)** Correlations between IL-18 and SARS-CoV-2-specific IgA. Ped = Pediatric (n=9); RA = Room Air (n=15); SO = Supplemental Oxygen (n=10). Bars show mean ± 95% CI

Figure S1: Adults not requiring oxygen are intermediate between children and adults who did. Principal component plot showing 95% confidence ellipses for pediatric samples, and samples from adults who did or did not require supplemental oxygen. RA = Room Air; SO = Supplemental Oxygen. N = 6 pediatric, 10 RA, 5 SO.

Figure S2: RT-qPCR of interferon-related genes. RT-qPCR was performed on indicated genes using 5 adult and 4 pediatric samples not included in the RNAseq analysis. Bars show mean $\pm$ 95% CI. Ped. = Pediatric. Fold change was calculated by the $2^{CT(ref)-CT}$ method using the mean adult value as the reference.

Supplemental Table 1: Demographic, clinical and laboratory findings of pediatric and adult patients with COVID-19

	Pediatric (n=12)	Adult (n=27)	p-value*
Age, years (mean $\pm$ SD)	6.54 $\pm$ 5.16	53.30 $\pm$ 22.73	< 0.001
Male:Female (n)	5:7	14:13	NS
Race/Ethnicity (n)			
Hispanic	6	18	NS
Black	3	6	
White	3	2	
Asian	0	1	
Symptom days prior to presentation	3.75 $\pm$ 3.91	4.44 $\pm$ 2.84	NS
Admission to hospital	5/12 (42%)	22/27 (81%)	0.02
Labs at admission			
Hemoglobin (g/dl)	12.60 $\pm$ 1.98 (n=5)	12.67 $\pm$ 1.60 (n=22)	NS
Platelets (x1000) (cells/ μ l)	330 $\pm$ 162.4 (n=5)	253.4 $\pm$ 83.87 (n=22)	NS
Total white blood cell	9500 $\pm$ 5317 (n=5)	9682 $\pm$ 3586 (n=22)	NS
ALC (cells/ μ l)	1680 $\pm$ 1047 (n=5)	1550 $\pm$ 1036 (n=22)	NS
ANC (cells/ μ l)	6760 $\pm$ 4368 (n=5)	7291 $\pm$ 3643 (n=22)	NS
C-reactive protein (mg/dl)	6.03 $\pm$ 10.48 (n=3)	10.48 $\pm$ 7.19 (n=20)	<0.0001
D-dimer (μ g/ml)	0.81 $\pm$ 0.59 (n=3)	2.38 $\pm$ 3.42 (n=21)	<0.0001
Respiratory support (n)			0.03
Room air	12	16	
Supplemental oxygen	0	7	
Mechanical ventilation	0	4	
Length of stay (days, admitted)	3.0 $\pm$ 1.73 (n=5)	10.36 $\pm$ 10.85 (n=22)	<0.0001
Mortality (n)	0/12	4/27	NS

SD, standard deviation; n, number; NS, not significant; ALC, absolute lymphocyte count; ANC, absolute neutrophil count

*Continuous variables were compared by Student's t test; categorical variables were compared by Fisher's exact test.

Supplemental Table 2: 50 top contributing genes to Principal Components (PC) PC1, PC2 and PC3 and their relative contribution.

PC1 (18.4%)		PC2 (12.9%)		PC3 (7.9%)	
Gene	Contribution	Gene	Contribution	Gene	Contribution
TREM1	0.173	CXCL10	0.262	IFIT2	0.225
IL1B	0.173	GNLY	0.197	ISG15	0.209
NLRP3	0.172	CXCL11	0.152	IFI44L	0.202
PLEK	0.163	HLA-DQA1	0.147	IDO1	0.200
ITGAX	0.158	IGHM	0.146	IFIT3	0.195
G0S2	0.155	IL4I1	0.143	OASL	0.184
AQP9	0.149	IL2RB	0.141	CXCL10	0.184
CSF3R	0.149	PAX5	0.139	IFIT1	0.178
DYSF	0.136	GZMB	0.139	DUOXA2	0.175
CD93	0.136	PRF1	0.138	COL6A1	0.165
PLAUR	0.133	RGS1	0.137	HERC6	0.151
SLC7A5	0.128	MUC13	0.137	RN7SK	0.150
LCP2	0.126	CCL4	0.136	DDX58	0.146
PDE4B	0.121	SAMD9L	0.135	XAF1	0.144
SRGN	0.121	ISG15	0.132	OAS2	0.140
SLA	0.120	CALHM6	0.130	DUOX2	0.137
HCK	0.114	IFIT2	0.124	LGALS17A	0.137
SPP1	0.114	GBP4	0.124	GBP4	0.132
CXCL8	0.113	CCL8	0.123	LIF	0.130
OSM	0.112	SERPINA3	0.115	SAMD9L	0.128
BCL2A1	0.112	FAM107A	0.113	OAS3	0.119
SPI1	0.112	CD69	0.111	ITGAM	0.118
SLC2A3	0.109	MUC2	0.110	SLC26A4	0.117
FGR	0.109	IGHA1	0.109	CMPK2	0.115
PIK3R5	0.108	GBP5	0.109	CXCL11	0.114
CSF2RB	0.108	ECM1	0.108	IFI44	0.114
CXCL5	0.107	IRF8	0.108	DDX60	0.114
IL1R2	0.107	FAM30A	0.108	USP18	0.113
CYBB	0.107	CCR5	0.107	OAS1	0.109
ADGRG3	0.106	LILRB1	0.105	IFITM1	0.108
FCGR2A	0.105	TRIM31	0.105	WARS1	0.104
SAMSN1	0.104	SIGLEC1	0.102	IGHG1	0.102
LOC388813	0.104	CXCL9	0.102	PARP14	0.099
CCL3	0.103	MMP10	0.102	LRRN2	0.099
C17orf107	0.101	HLA-DOA	0.101	RSAD2	0.098
HCAR3	0.101	HLA-DPA1	0.100	BATF2	0.097
CD83	0.101	ACOD1	0.100	TNFSF10	0.096
ITGAM	0.100	CCL3	0.099	ATP10B	0.094
TNFRSF1B	0.100	CMKLR1	0.098	FCGBP	0.092
LCP1	0.100	IGKC	0.097	ETV7	0.090
INHBA	0.099	IFIT3	0.097	ISG20	0.090
MCEMP1	0.097	HSD11B2	0.097	AMY1C	0.089

PELATON	0.097	LGALS17A	0.097	MX1	0.087
ZEB2	0.096	KRT13	0.095	CXCL5	0.086
LAPTM5	0.095	THSD7A	0.095	MKI67	0.085
FFAR2	0.095	SERPING1	0.091	MX2	0.085
CCL3L1	0.095	MTCO1P12	0.090	CES1P1	0.085
CCL3L3	0.095	ANPEP	0.090	MMP9	0.085
LINC00528	0.093	IFIT1	0.089	TRIM31	0.085
ALOX5AP	0.092	ZAP70	0.086	IFI6	0.082

Supplemental Methods

RNA sequencing

Libraries were prepared at the Yale Center for Genome Analysis using the NEBNext rRNA Depletion Kit (E6310L). Individual samples or pools from 2 patients of similar age and outcome (n=4 pools, adults) were normalized to 1.2nM and loaded on an Illumina NovaSeq S4 flow cell to generate 30M read-pairs per sample. Samples were checked for read quality and adapter contamination using FastQC and aligned to transcripts using the GENCODE transcript sequences (v33) as the reference file with Salmon (29). All analyses in R were performed using R version 4.0.3. Transcripts were mapped to genes using tximport. Differential gene expression analysis was performed with DESeq2 (30). Heatmaps were generated using the pheatmap package. Principal components analysis was performed with the *prcomp* function using all genes with a non-zero total read count. Prior to PCA, data were transformed with the *vst* function in DESeq2. PCA results were visualized with the factoextra package. For gene set enrichment analyses, Hallmark (h) and GO (c5.go) datasets were downloaded from MSigDB (Broad Institute) and analysis performed in R with the fgsea package using 1000 permutations.

Real-Time Quantitative Reverse Transcription PCR

qPCR was performed using the TaqMan Gene Expression Master Mix (Applied Biosystems, 4369016). Data were analyzed by the $2^{-\Delta\Delta Ct}$ method, using the mean adult values as the reference. Primers/probes were from ThermoFisher: MX1 (Hs00895608_m1), MX2 (Hs01550811_m1), IFNA1 (Hs00256882_s1), IFI44 (Hs00951349_m1), IFIT1 (Hs03027069_s1), IL17A (Hs00174383_m1), IFNG (Hs00989291_m1), RPLPO (Catalog No. 4326314E).

Cytokine and Antibody Measurements

Data from Luminex assays were acquired on a Luminex Magpix (Luminex Corporation) and analyzed in the Milliplex Analyst program (Millipore). Total IgA was measured using the IgA Human ELISA Kit (Invitrogen, BMS2096), and total IgG measured using the IgG Human ELISA

Kit (Invitrogen, BMS2091). ELISA data were acquired on a Spectra Max M5 using SoftMax Pro 7.1 GxP software (both Molecular Devices).